日韩欧美 a级,国产又色又爽又刺激在线观看,偷偷色噜狠狠狠狠的777米奇,浮妇高潮喷白浆视频

Topiroxostat

    98%

Topiroxostat

源葉(MedMol)
S85842
577778-58-6
C13H8N6
248.2428
品牌 貨號(hào) 產(chǎn)品規(guī)格 價(jià)格(RMB) 庫存(上海) 北京 武漢 南京 購買數(shù)量
源葉(MedMol) S85842-5mg 98% ¥280.00元 >10 - - -
源葉(MedMol) S85842-10mg 98% ¥400.00元 >10 2 - -
源葉(MedMol) S85842-50mg 98% ¥1200.00元 >10 - - -
源葉(MedMol) S85842-100mg 98% ¥1520.00元 >10 - - -
源葉(MedMol) S85842-250mg 98% ¥2800.00元 >10 - - -
產(chǎn)品介紹 參考文獻(xiàn) 質(zhì)檢證書(COA) 摩爾濃度計(jì)算器 相關(guān)產(chǎn)品

產(chǎn)品介紹

Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment
產(chǎn)品描述: Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment
靶點(diǎn): IC50: 5.3 nM (XOR) Ki: 5.7 nM (XOR);P450;ROS;XanthineOxidase
體外研究: These potent and more sustained effects of Topiroxostat (FYX-051, compound 39) have been confirmed by a crystallographic analysis of XOR-Topiroxostat complex. The cyano group of Topiroxostat has been reported to play an important role in the binding activity between Topiroxostat and XOR. This is attributable to the formation of a hydrogen bond between Asn 768 of XOR and the cyano group of Topiroxostat
體內(nèi)研究: Topiroxostat (FYX-051; 0.03-10 mg/kg; oral administration; for 1 hour; male Wistar/ST strain rats) treatment shows a potent and long-lasting hypouricemic effect in a rat model of potassium oxonate-induced hyperuricemia. The Cmax and bioavailability of Topiroxostat (FYX-051, compound 39) are as high as 4.62 μg/mL (3 mg/kg) and 69.6%, respectively. Moreover, the t1/2 value of Topiroxostat is 19.7 hours. Animal Model: Male Wistar/ST strain rats (7 weeks old) injected with potassium oxonate Dosage: 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg Administration: Oral administration; for 1 hour Result: Caused a dose-dependent decrease in serum urate levels with an extremely low ED50 of 0.15 mg/kg, evaluated at 1 h after oral administration.
參考文獻(xiàn): 1. Sato T, et al. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9. 2. Matsumoto K, et al. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011 Jan;336(1):95-103.
溶解性: soluble  in  DMSO
保存條件: -20℃
配置溶液濃度參考:
1mg 5mg 10mg
1 mM 4.028 ml 20.142 ml 40.283 ml
5 mM 0.806 ml 4.028 ml 8.057 ml
10 mM 0.403 ml 2.014 ml 4.028 ml
50 mM 0.081 ml 0.403 ml 0.806 ml
注意: 部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。

參考文獻(xiàn)

質(zhì)檢證書(COA)

如何獲取質(zhì)檢證書(COA)?
請輸入貨號(hào)和一個(gè)與之匹配的批號(hào)。
例如:
批號(hào):JS298415 貨號(hào):S20001-25g
在貨品標(biāo)簽上如何找到貨號(hào)和批號(hào)?

摩爾濃度計(jì)算器

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

=
×
×

相關(guān)產(chǎn)品